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Fulminant hepatitis (FH) is a life-threatening liver disease characterised by intense immune attack andmassive liver cell death.The
common precore stop codonmutation of hepatitis B virus (HBV), A1896, is frequently associated with FH, but lacks specificity.This
study attempts to uncover all possible viral nucleotides that are specifically associatedwith FH through a compiled sequence analysis
of FH and non-FH cases from acute infection. We retrieved 67 FH and 280 acute non-FH cases of hepatitis B from GenBank and
applied support vector machine (SVM) model to seek candidate nucleotides highly predictive of FH. Six best candidates with top
predictive accuracy, 92.5%, were used to build a SVMmodel; they are C2129 (85.3%), T720 (83.0%), Y2131 (82.4%), T2013 (82.1%),
K2048 (82.1%), and A2512 (82.1%). This model gave a high specificity (99.3%), positive predictive value (95.6%), and negative
predictive value (92.1%), but only moderate sensitivity (64.2%). We successfully built a SVMmodel comprising six variants that are
highly predictive and specific for FH: four in the core region and one each in the polymerase and the surface regions.These variants
indicate that intracellular virion/core retention could play an important role in the progression to FH.
1. Introduction
In hepatitis B virus (HBV) infection, fulminant hepatitis
(FH) occurs in less than 1% of adult infections but is
associated with nearly 70% mortality [1]. The pathogenesis
of FH is largely unclear. This rapidly progressive liver injury
is believed to be attributed to a sudden strong cytotoxic
T lymphocyte (CTL) response to the presence of HBV,
enhanced viral replication, and/or retention of viral capsid in
HBV-infected hepatocytes [2, 3]. The result of these events
is extensive hepatocyte apoptosis and necrosis leading to an
immense loss of liver function that is deadly to HBV-infected
individuals.
HBV is classified under the family ofHepadnaviridae.The
partially double-stranded DNA genome of the virus contains
four overlapping open reading frames (ORF), namely, the
polymerase, surface, core, andX genes.While the polymerase
and X genes are essential for viral replication, the core
gene encodes the core protein (HBcAg) and excretory e
antigen (HBeAg), and the surface gene encodes three surface
antigens, namely, the large pre-S1, middle pre-S2, and small S
proteins [4].
The mutations linked to the development of FH are
mainly found in the precore region, the most frequently
reported being A1896 [5–7]. A1896 abolishes the expression
of HBeAg that is known to induce immune tolerance [8].
It is believed that this removal would lead to the loss of
immune tolerance and the consequent enhanced immune
attack against hepatocytes. In addition, frame-shiftmutations
in the precore region have been observed in FH [9]. Germane
to this, the predominance of HBV genotypes B and D in
FH could be explained by the high occurrence of A1896 in
these genotypes as compared to genotypes C and A [10]. Less
common mutations, such as G1862T, G1899A, and A2339G,
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have also been reported [11, 12] but the relevance of these
mutations to FH needs further evaluation.
It is currently possible to search for more credible viral
genomic variations associated with FH due to increasing
numbers of HBV genomes being sequenced worldwide.
Through these viral variants, we attempted to provide insights
into whether the underlying mechanisms of FH favour
host massive immune attack, viral-induced cytopathy due to
intracellular virion/capsid accumulation, or both.
2. Materials and Methods
2.1. Retrieval of HBV Genome Sequences. HBV genomes of
FH and non-FH hepatitis B acute infections were retrieved
from the National Centre for Biotechnology Information
(NCBI) Nucleotide Database on 20 April 2017. The keywords
used in advanced search were “Hepatitis B virus”, “complete
genome”, and “fulminant” or “acute”. The genome length
in the search was restricted to 2,800 to 3,400 nucleotides
(nt) as the typical HBV genome size is about 3.2k nt. The
initial search produced 98 and 726 hits for FH and non-
FH cases, respectively. Acute-on-chronic hepatitis and acute-
on-chronic liver failure, which resulted from chronic infec-
tion, were excluded from further analysis. After excluding
unrelated hits, the final search yielded 67 FH and 280 acute
non-FH cases; one case was sub-FH. Acute non-FH cases
were used as the control group for sequence comparison in
this study. The accession numbers of these HBV genomes
are provided in Suppl Table 1. Geographic data of these
HBV isolates was also retrieved from GenBank database and
published papers wherever available.
2.2. Sequence Analysis. HBV genomes were genotyped using
the Viral Genotyping Tool available at the NCBI website [13].
Sequence alignmentwas carried out usingMAFFT6.849 [14].
The alignment was edited using BioEdit [15]. The reference
HBV genome used for the numbering of nucleotide positions
wasD50521.1.The completeHBVgenome sequences fromFH
and non-FH cases were compared and the frequency of each
informative candidate nucleotide was determined.
2.3. Phylogenetic Analysis. A neighbour-joining (NJ) tree
was reconstructed for the complete genomes of HBV in the
phylogenetic analysis, using MEGA version 7.0.18 software,
with a Kimura-2 parameter nucleotide substitution model,
uniform rate among sites, and complete deletion for gaps [16–
18]. The reliability of the branching orders was evaluated by a
bootstrap analysis of 1,000 replicates.
2.4. Statistical Analysis and Interpretation of Results. Statisti-
cal analyses were performed using the Statistical Program for
Social Sciences (SPSS 17.0 for windows, SPSS, Inc., Chicago,
IL). Fisher’s exact test was applied to examine the association
between nucleotide type and disease state. A 𝑃 value of <0.05
was taken as significant.
2.5. Support Vector Machine Modelling. To avoid false pos-
itive discovery, observations were randomised 20 times to
benchmark the maximum random guess accuracy; in this
case, it was found to be 81.8% (284/347). Fifty-five informative
candidate nucleotides that passed the maximum random
guess accuracy were identified based on the MAFFT-aligned
sequence data. These 55 nucleotides were sorted by accuracy
in a descending order before proceeding to feature selection
processes. Single round of brute force selection of 6 candidate
nucleotides at a timeusing the 55 nucleotides is not possible as
it requires high computational resource. Two rounds of brute
force selection procedures were implemented with support
vector machine (SVM) dot kernel algorithm in RapidMiner
7.2.001 [19, 20]. The first round generated a list consisting
of three candidate nucleotides in combination that gave the
highest accuracy. The top 25 most informative candidate
nucleotideswere determined in this round.The second round
of brute force selection was then applied to further reduce the
number of the nucleotides to a maximum of six, in order to
minimise the risk of overfitting the SVMmodel.
The SVM model was then used to assess the predictive
values of the candidate nucleotides thus selected. For each
feature, the most frequent nucleotide type across both classes
was coded as 1 and others were coded as 0. To reduce biases
due to uneven sampling size, the predictive accuracy of the
candidate nucleotides was assessed using a balanced training
dataset consisting of 67 FH cases and 67 randomly chosen
cases from the control group. This was to benchmark the
random guess accuracy at 50%. The random sampling for
cases from control group was repeated 1,000 times. A 5-
fold cross-validation was carried out for the 1,000 balanced
datasets.
Predictive values were expressed in terms of overall or
average accuracy, sensitivity, specificity, positive predictive
value (PPV), and negative predictive value (NPV). “Overall”
referred to all cases and controls, whereas “average” was
used for the calculation of predictive values in 5-fold cross-
validation using the balanced sampling method. Accuracy
was defined as the sum of correct guesses of FH and acute
non-FH cases over the total number of both cases. Sensitivity
was calculated by dividing the sum of correctly identified FH
cases with a marker over all FH cases, whereas specificity was
obtained by dividing the sum of correctly identified control
cases without the marker over all control cases. The PPV
was calculated by dividing the sum of correctly identified
FH cases over all positive predictions, and the NPV was
calculated by dividing correctly identified control cases over
all negative predictions.
3. Results
3.1. Geographical Distribution, Genotype, and Phylogenetic
Analysis. Of 67 cases in FH, 44 were from Asian countries
(mainly China and Japan; 65.7%), 23.9% from the West
(Europe and the USA), 6 from Africa (9.0%), and 1 from the
Middle East (1.5%), whereas, in 280 acute non-FH cases, the
corresponding percentages were 169 from Asia (60.4%), 50
from the West (17.9%), 5 from Africa (1.8%), and 56 from
South America (20.0%). The geographical distribution of FH
and non-FH groups seems to be similar. Most of the HBV
are of genotypes A–D (Table 1). Genotypes B and D are
predominant in FH cases as compared with acute non-FH
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Table 1: Genotype distribution of fulminant and acute nonfulmi-
nant hepatitis B viral genomes retrieved from NCBI.
Genotype Fulminant,𝑁 = 67 (%) Acute,𝑁 = 280 (%)
A 8 (11.9) 65 (23.2)
B 22 (32.8) 31 (11.1)
C 22 (32.8) 112 (40.0)
D 15 (22.4) 26 (9.3)
F 0 (0.0) 40 (14.3)
G 0 (0.0) 1 (0.4)
H 0 (0.0) 4 (1.4)
I 0 (0.0) 1 (0.4)
NCBI: National Center for Biotechnology Information.
cases (𝑃 < 0.001). Genotypes F, G, H, and I were only seen in
acute non-FH cases. Phylogenetic analysis of HBV genotypes
A–D (Suppl Figure 1) showed that FH cases and controls
did not form distinct clusters. However, some cases clustered
together due to either similar geographical location (such as
Belgium cases in acute hepatitis) or distinct genotype (such as
genotype F cases in acute hepatitis) in single disease outcome
study.
3.2. Viral Candidate Nucleotides Potentially Predictive of FH.
A total of 55 informative candidate nucleotides that passed
the maximum random guess accuracy were identified (Suppl
Table 2). These nucleotides were sorted in the descending
order based on accuracy values. The top 25 were chosen
in the first round of brute force selection in a list of
combination of three nucleotides; they were A1410, A2345,
A2512, B3106, C123, C132, C280, C774, C2129, D2303, G1981,
G2003, G2173, G2430, G2431, K2048, T343, T720, T2013,
T2755, T2979,W1677, Y2092, and Y2131.These 25 nucleotides
proceeded to the second round of brute force selection. A
list consisting of 5-6 candidate nucleotides in combinations
was generated using SVM modelling (Suppl Table 3). The
list with the highest accuracy, 92.51%, was selected; they are
T720, T2013, K2048, C2129, Y2131, and A2512 (Table 2). Two
variants coexist in some FH cases (Suppl Table 4). A 5-fold
cross-validation method repeated 1,000 times was applied to
evaluate the predictability of the candidate nucleotides in the
list, and balanced sampling size (𝑁 = 67) was adopted to
reduce the biases in data analysis. Average predictive accuracy
was calculated to be 81.1% ± 0.70%, sensitivity 63.7% ±
1.41%, specificity 98.5% ± 0.00%, PPV 97.7% ± 0.05%, and
NPV 73.1% ± 0.74%. Overall predictive accuracy was 92.5%,
sensitivity 64.2%, specificity 99.3%, PPV 95.6%, and NPV
92.1%.
4. Discussion
FH is a dreaded complication of HBV infection.The identifi-
cation of FH-associatedHBVmutations could provide amore
precise insight into the disease pathogenesis of FH. We built
a SVM model that is highly predictive and specific for the
development of FH. It consists of six novel HBV nucleotide
variants, four of which are in the core gene. Here, we attempt
to explain the rationales of these nucleotide markers in the
pathogenesis of FH.
The core protein, also known as HBcAg, has 183 residues,
of which 149 at the N-terminus belong to the assembly
domain, and 34 at the C-terminus are the RNA-binding
domain [21–23]. All four of the core variants we identified,
T2013, K2048, C2129, and Y2131, corresponding to residues
38, 50, 77, and 77, respectively, fall within the assembly
domain, which forms the shell of viral capsid. Mutations
in this domain may cause inefficient capsid assembly and
subsequently retention of capsid within hepatocytes that
could cause liver injury [24]. In a study on HBV-infected
human liver biopsies, the cytoplasmic localisation of HBcAg
was related to more hepatic injury [25]. Immunohistochem-
ical examination of liver tissue samples showed stronger
staining of HBcAg in the nucleus of tissues from FH patients
than in tissues from acute hepatitis patients [2]. These two
studies indicate that excessive intracellular accumulation of
virion/HBcAg is cytopathic to hepatocytes.
At residue 77 ofHBcAg, there is aG-C (Glu toGln) switch
in nucleotide 2129 (Glu77Gln; codons GAA to CAA) that
is accompanied by a change in charge from acidic to polar
uncharged (but no change in secondary structure), as well as
anA-Y (Glu toAsp) change in nucleotide 2131 (GAA toGAY),
which is accompanied by a change in secondary structure
from alpha-helix to turn-and-loop (but no change in charge).
These G2129C and A2131Y changes could be important for
the intracellular retention of the HBV virion. Supporting
evidence for this hypothesis comes from the observations
of other workers that concomitant changes of Glu77Gln
with Pro79Gln, Ala80Pro, and Ser181Pro in the core protein
appear to promote nuclear retention of HBcAg [24] and
that Glu77Ala in silico destabilises the core residue-surface
antigen interface which is essential for the secretion of virions
after assembly [26].
In the A2013T variant, there is a switch from Tyr to Phe
(TAT to TTT). Tyr can be phosphorylated and glycosylated,
but not Phe. In general, the phosphorylation of amino
acids plays a role in signalling, whereas glycosylation affects
protein secretion, structural formation, and antigenicity.
Although there is no change in structure and charge in
A2013T, an alteration in the posttranslational modification
capability can potentially affect the assembly efficiency of
the viral capsid. Failure in the HBcAg assembly might
then cause excessive accumulation of viral capsids within
hepatocytes.
In C2048K, corresponding to residue 38, there is a switch
from Pro to Ala/Tyr (CCT to GCT/TAT) at residue 50, along
with a change in charge from polar to nonpolar. Such an
amino acid alteration might hinder the formation of the
turn-and-loop structure in HBcAg. As C2048K has not, so
far, been implicated in disease pathogenesis, the impact of
this variant on virion/core protein retention warrants further
investigation. In addition, C2048K is located within T helper
CD4+ epitopes of HBcAg [27] and, hence, is expected to
affect host immune response to HBV. However, there is no
direct evidence that structural change in the residue 50 in the
Th CD4+ epitope could invoke a strong immune attack on
hepatocytes.
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Table 2: The best combination of six candidate nucleotides of HBV associated with fulminant hepatitis was chosen from top 55 candidate
nucleotides using brute force selection method implemented with SVM dot kernel algorithm.
Nucleotide Gene/regulatory element Fulminant, 𝑛 = 67 (% sensitivity) Acute, 𝑛 = 280 (% specificity) % accuracya 𝑃 valueb
C2129 Core 17 (25.4) 1 (99.6) 85.3 1.897𝐸 − 12
T720 Surface/polymerase-RT 9 (13.4) 1 (99.6) 83.0 2.000𝐸 − 06
Y2131 Core 6 (9.0) 0 (100.0) 82.4 4.300𝐸 − 05
T2013 Core 5 (7.5) 0 (100.0) 82.1 2.371𝐸 − 04
K2048 Core 5 (7.5) 0 (100.0) 82.1 2.371𝐸 − 04
A2512 Polymerase-TP 5 (7.5) 0 (100.0) 82.1 2.371𝐸 − 04
HBV, hepatitis B virus; SVM, support vector machine; RT, reverse transcriptase; TP, terminal protein; a% accuracy = (67 × % sensitivity + 280 × %
specificity)/(67 + 280); bFisher’s exact test; 𝑃 value of 1.897𝐸 − 12 is equivalent to 1.897 × 10−12.
The C720T variant is corresponding to residue 189 of
HBsAg. This substitution of Thr (ACT) with Ile (ATT) is
not associated with structural change but a shift from polar
to nonpolar charge state. The residues 96–122 and residues
169–195 of HBsAg participate in the capsid interaction with
core protein in residues 67–96 in order to promote the
formation of an infectious virus [26]. The absence of such
an interaction may cause intracellular retention of virions,
which subsequently induce cytopathic effects in hepatocytes.
The hepatitis B small surface antigen (HBsAg) is believed
to have at least 3 transmembrane domains (TM1, TM2, and
TM3) [28]. The C720T variant falls within the TM3 domain
(containing residues 161–226). Nonsynonymous amino acid
mutations, such as S167L andQ181STOP, in the TM3 domain,
reduce HBsAg reactivity in occult HBV infections [29,
30]. However, whether the C720T variant (T189I) possesses
immune-escape capability that allows excessive accumulation
of virions within hepatocyte requires further investigation.
Terminal (TP) is one of the protein domains in the
polymerase enzyme. It acts as a protein primer for viral DNA
synthesis. TP-epsilon RNA binding is required for the pack-
aging of both polymerase and pregenomic RNAs (pgRNA)
into nucleocapsids [31]. TP residues 67–80 are critical for such
binding [32]. B2512A corresponds to residue 69 of TP. The
residue falls within the TP priming loop region. In acute non-
FH cases, it seems to be heterogeneous. B2512A converts Ile
(ATC), Val (GTC), Cys (TGC), or Thr (ACT) to Asn (AAY).
The former three amino acid residues incline to form a beta-
sheet structure, whereas the latter one hinders the formation
of the beta-sheet structure. Such structural hindrance could
inhibit the TP-RNA-binding function. Consequently, this
would cause accumulation of viral capsids and pregenomic
RNAs (pgRNAs) in hepatocytes.
Surprisingly, A1896, themost commonly citedmarker for
FH, is not among the 6 variants selected for building the
SVMmodel.This could be due to its low predictive specificity.
The link between A1896 and FH has been demonstrated
in Japanese studies [33, 34], but not in studies from other
countries like United States and Germany [35]. We also did
not findHBV genotyping to be useful for the identification of
FH cases as genotypes A–D are associated with both FH and
acute non-FH. On the other hand, we did not find genotypes
F–I in any of the FH cases in our series. Hence, these
genotypes could be investigated further for their potential
significance as biomarkers for non-FH.
In conclusion, we identified six HBV variants (4 in the
core, 1 in the polymerase-TP, and 1 in the surface/polymerase-
RT region) that are highly predictive and specific for the
identification of patients at risk for FH. These viral variants
could play an important role in the disease progression to
FH by causing excessive accumulation of viral capsids in
hepatocytes. Hence, our findings favour the hypothesis of
viral-induced cell death over hepatic immune attack, being
an important factor in the pathogenesis of FH.
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Supplementary Materials
Supplementary 1. Suppl Figure 1: the evolutionary historywas
inferred using the neighbour-joiningmethod.Thepercentage
of replicate trees in which the associated taxa clustered
together in the bootstrap test (1000 replicates) are shown
next to the branches. The tree is drawn to scale, with
branch lengths in the same units as those of the evolu-
tionary distances used to infer the phylogenetic tree. The
evolutionary distances were computed using the Kimura 2-
parameter method and are in the units of the number of base
substitutions per site. The analysis involved 347 nucleotide
sequences. All positions containing gaps and missing data
were eliminated. There were a total of 2,362 positions in
the final dataset. Evolutionary analyses were conducted in
MEGA7.
Supplementary 2. Suppl Table 1: genotype and geographical
distribution of fulminant and acute hepatitis B.
Supplementary 3. Suppl Table 2: top 55 candidate nucleotides
associated with fulminant hepatitis B.
Supplementary 4. Suppl Table 3: list of top 25 most informa-
tive nucleotide variants associated with fulminant hepatitis B
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in combinations generated using SVM modelling with brute
force selection.
Supplementary 5. Suppl Table 4: frequency of top 6 nucleo-
tide variants inHBV isolates of fulminant and acute hepatitis.
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